Futura Medical (FRA:GYX) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Futura Medical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Futura Medical's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Futura Medical could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Futura Medical's Cash-to-Debt or its related term are showing as below:

FRA:GYX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, Futura Medical's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

FRA:GYX's Cash-to-Debt is ranked better than
99.8% of 1524 companies
in the Biotechnology industry
Industry Median: 6.225 vs FRA:GYX: No Debt

Futura Medical Cash-to-Debt Historical Data

The historical data trend for Futura Medical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Futura Medical Cash-to-Debt Chart

Futura Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Futura Medical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Futura Medical's Cash-to-Debt

For the Biotechnology subindustry, Futura Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Futura Medical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Futura Medical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Futura Medical's Cash-to-Debt falls into.

Futura Medical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Futura Medical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Futura Medical had no debt ⁽¹⁾.

Futura Medical's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Futura Medical had no debt ⁽¹⁾.

Futura Medical (FRA:GYX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Futura Medical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Futura Medical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Futura Medical (FRA:GYX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Futura Medical PLC (FRA:GYX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

FAMDF:USA FUM:UK

Address

40 Occam Road, Surrey Technology Centre, Guildford, Surrey, GBR, GU2 7YG

Website

https://www.futuramedical.com

Futura Medical PLC is a pharmaceutical company based on technology. The company manufactures drugs and is based in the United Kingdom. The company lays primary focus on topically applied pharmaceutical drugs and medical devices which are developed using a efficient and proprietary transdermal delivery technology, DermaSys. DermaSys is a versatile technology that can be customized to suit the specific active compound being used and the therapeutic indication. The company's products are used mainly for the treatment of erectile dysfunction and pain relief.

Futura Medical (FRA:GYX) Headlines

No Headlines

Futura Medical (FRA:GYX) Cash-to-Debt : No Debt (1) (As of Dec. 2023)